

vigiGrade™ - Completeness score

Latvia

The vigiGrade™ - Completeness score is a system to measure the amount of information provided on Individual Case Safety Reports (ICSRs).

This document contains the Completeness scores for ICSRs from your country over the past 5 years, presented as three different reports:

1. Completeness score by country - overview for all countries
2. Average completeness score, Latvia
3. Completeness score by field, Latvia

Please refer to the supporting document "*Technical description to vigiGrade™ Completeness score*" for more information about the completeness score. Here you will find a detailed description of the calculation of scores, for your reference.

If you would like further information on the dimensions **Time to onset**, **Age at onset** and **Dosage**, more detailed graphs on the calculation are available on request. These graphs show the completeness of all specific fields contributing to the total field score for these dimensions.




If you have any questions, please contact us at vigibase@who-umc.org.

Please note that Completeness score is one of several aspects of ICSR quality.

In any ICSR management system it is also vital to consider the balance between quality, quantity and frequency of ICSR submissions in order to focus available resources optimally. You can always contact us at vigibase@who-umc.org for additional statistics for your country on quantity and frequency of submissions to VigiBase.


vigiGrade Completeness score over time by country

Calculated on all ICSRs entered into the WHO global ICSR database between 20110101 and 20160601




Average Completeness score, Latvia


Average Completeness score over time



Total number of ICSRs per quarter (from all countries)




Number of ICSRs per quarter (Latvia)



Completeness score by field, Latvia

NC Name	Report format	E2B date	Member date
State Agency of Medicines of Latvia	E2B	2010-01-28	2002

Average Completeness score over time by field



— Age at onset	— Report type	— Comments	— Indication	— Outcome
— Patient sex	— Primary reporter	— Dosage	— Time to onset	- - - Completeness
— Country				

Age at onset	Age of the patient at the time the reaction started.
Patient sex	Sex of the patient.
Country	Country where the ICSR was originally reported, i.e. the country where the reporter documented the case.
Report type	Type of report, i.e. 'spontaneous report', 'report from study' or 'other'.
Primary reporter	Qualification of the primary reporter, e.g. physician or pharmacist.
Comments	Free text information, such as narrative text or reporter comments.
Dosage	Total daily dose for suspected and interacting drugs reported on the case. Concomitant drugs are not included within the score. A full score is given if the total daily dose is given or can be calculated.
Indication	Indication for use of the drug, i.e. the reason the patient was taking each of the suspected and interacting drugs. Concomitant drugs are not included within the score. A full score is given if the Indication can be mapped to a standard terminology (MedDRA, ICD8, ICD9 or ICD10).
Time to onset	Time elapsed from drug intake to the start of the reaction, for each drug-reaction combination reported on the case. Concomitant drugs are not included within the score. Imprecise information is penalized, for example incomplete dates for reaction start and drug start.
Outcome	Outcome of each reported reaction, e.g. 'recovered', 'not recovered' or 'death'.
Completeness	Average Completeness, which is calculated from all the pieces of information above.

Year Quarter	Age at onset	Patient sex	Country	Report type	Primary reporter	Comments	Dosage	Indication	Time to onset	Outcome	Completeness	
2011	1	0.95	0.92	1.00	1.00	1.00	1.00	0.38	0.94	0.95	0.84	0.83
	2	1.00	1.00	1.00	1.00	1.00	1.00	0.73	0.95	0.97	1.00	0.95
	3	0.98	1.00	1.00	1.00	1.00	1.00	0.57	0.94	0.95	0.78	0.85
	4	1.00	1.00	1.00	1.00	1.00	1.00	0.57	0.89	0.75	0.98	0.81
2012	1	0.98	1.00	1.00	1.00	1.00	1.00	0.79	0.84	0.67	0.83	0.74
	2	1.00	1.00	1.00	1.00	1.00	1.00	0.60	0.88	0.65	0.84	0.75
	3	0.94	0.94	1.00	1.00	1.00	1.00	0.65	0.74	0.87	0.92	0.78
	4	1.00	1.00	1.00	1.00	1.00	1.00	0.70	0.94	0.97	0.79	0.88
2013	1	0.96	1.00	1.00	1.00	1.00	1.00	0.75	0.83	0.82	0.71	0.76
	2	1.00	1.00	1.00	1.00	1.00	1.00	0.68	0.83	0.96	0.89	0.87
	3	0.91	1.00	1.00	1.00	1.00	1.00	0.76	0.87	0.80	0.83	0.79
	4	0.91	1.00	1.00	1.00	1.00	1.00	0.62	0.74	0.83	0.80	0.77
2014	1	0.98	0.98	1.00	1.00	1.00	1.00	0.71	0.85	0.83	0.84	0.81
	2	0.97	1.00	1.00	1.00	1.00	1.00	0.66	0.81	0.72	0.79	0.75
	3	0.93	1.00	1.00	1.00	1.00	1.00	0.65	0.81	0.88	0.83	0.82
	4	1.00	1.00	1.00	1.00	1.00	1.00	0.41	0.87	0.86	0.61	0.76
2015	1	0.92	1.00	1.00	1.00	1.00	1.00	0.72	0.92	0.85	0.85	0.84
	2	0.93	0.98	1.00	1.00	1.00	1.00	0.77	0.87	0.86	0.87	0.84
	3	0.93	0.98	1.00	1.00	1.00	1.00	0.65	0.86	0.72	0.81	0.76
	4	0.92	0.98	1.00	1.00	1.00	1.00	0.59	0.85	0.88	0.85	0.83
2016	1	0.96	1.00	1.00	1.00	1.00	1.00	0.75	0.89	0.85	0.92	0.85
	2	0.93	1.00	1.00	1.00	1.00	1.00	0.70	0.91	0.83	0.72	0.79